New Clinical testing segments to watch out for in 2018

Multi-Target Liquid Biopsy, Genetic Health Testing, Syndromic Testing, Microbial Imbalances

Advancements in technology and clinical medicine will have significant influence on IVD market. Liquid biopsy-based companion diagnostics; direct-to-consumer (DTC) genetic health testing ; detecting microbial imbalances; Infectious disease pathogen DNA testing and a number of totally disparate phenomena have come together to shape the future IVD industry.

Based on the market research, Kalorama Information, a division of, has published a white paper titled 5 IVD Market Trends to Watch in 2018.

According to the white paper the following trends should be on the radar of all progressive IVD companies.

Liquid Biopsy and Multi-Target Liquid Biopsy

Non-invasive testing particularly for cancer diagnostics will continue to feature as one of the most promising trends of 2018. While companies like Qiagen are betting big on its industry-leading portfolio of liquid biopsy solutions addressing all major technologies; others are finding novel ways to automate the process. According to the Kalorama report, US based PAXgene technology now offers automated solutions for the collection, stabilization and purification of circulating cell-free DNA from blood samples. It allows whole blood to be drawn and stored at cooled and ambient temperatures for up to seven days before samples are processed and tested for the presence of circulating cell-free …

To read more subscribe
Show More

Related Articles

Leave a Reply